跳至主要内容
临床试验/NCT00911794
NCT00911794已完成不适用

Pulmonary Therapy and Supplemental Written Disclosure Therapy for Chronic Lung Disease

Winthrop University Hospital0 个研究点目标入组 66 人开始时间: 2007年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
66
主要终点
Dyspnea and quality of life

研究概览

简要总结

The purpose of this study is to determine whether Written Disclosure Therapy (WDT) is of any benefit to patients with chronic lung diseases who are participating in pulmonary rehabilitation.

详细描述

Chronic lung diseases are typically associated with impaired quality of life, stress, and anxiety. Written disclosure therapy (WDT) reduces stress in patients with a variety of chronic illnesses. We sought to determine if written disclosure therapy benefits patients with chronic lung diseases when it is added as a component to the pulmonary rehabilitation program.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of COPD or Pulmonary Fibrosis
  • First time participants in Pulmonary Rehabilitation program

排除标准

  • Prior significant psychiatric illness
  • Inability to complete the questionnaires
  • Inability cooperate with spirometry
  • Inability or to participate in outpatient follow-up over the six-month

结局指标

主要结局

Dyspnea and quality of life

时间窗: Two-month and six-month time

次要结局

  • Six-minute walk distance(Two-month and six-month time)
  • Spirometry values (FEV1 and FVC)(Two-month and six-month time)

研究者

申办方类型
Other

相似试验